Lucid Capital initiated coverage of MeiraGTx (MGTX) with a Buy rating and $50 price target MeiraGTx is developing next-generation, genetic medicines to potentially unlock cures in chronic diseases, the analyst tells investors in a research note. The firm says the company is “providing a toolbox to pharma.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX: